Intravesical Mycobacterium brumae triggers both local and systemic immunotherapeutic responses against bladder cancer in mice by Noguera Ortega, Estela et al.
1SCIEnTIfIC REPORTS |  (2018) 8:15102  | DOI:10.1038/s41598-018-33253-w
www.nature.com/scientificreports
Intravesical Mycobacterium brumae 
triggers both local and systemic 
immunotherapeutic responses 
against bladder cancer in mice
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The standard treatment for high-risk non-muscle invasive bladder cancer (BC) is the intravesical 
administration of live Mycobacterium bovis BCG. Previous studies suggest improving this therapy by 
implementing non-pathogenic mycobacteria, such as Mycobacterium brumae, and/or different vehicles 
for mycobacteria delivery, such as an olive oil (OO)-in-water emulsion. While it has been established 
that BCG treatment activates the immune system, the immune effects of altering the mycobacterium 
and/or the preparation remain unknown. In an orthotopic murine BC model, local immune responses 
were assessed by measuring immune cells into the bladder and macromolecules in the urine by flow 
cytometry and multiplexing, respectively. Systemic immune responses were analyzed by quantifying 
sera anti-mycobacteria antibody levels and recall responses of ex vivo splenocytes cultured with 
mycobacteria antigens. In both BCG- and M. brumae-treated mice, T, NK, and NKT cell infiltration in the 
bladder was significantly increased. Notably, T cell infiltration was enhanced in OO-in-water emulsified 
mycobacteria-treated mice, and urine IL-6 and KC concentrations were elevated. Furthermore, 
mycobacteria treatment augmented IgG antibody production and splenocyte proliferation, especially 
in mice receiving OO-in-water emulsified mycobacteria. Our data demonstrate that intravesical 
mycobacterial treatment triggers local and systemic immune responses, which are most significant 
when OO-in-water emulsified mycobacteria are used.
Bladder cancer (BC) is the 7th most common cancer in men worldwide1. At the time of diagnosis, the tumor is 
typically confined to the mucosa layer and is called non-muscle invasive BC (NMIBC). After resection of the 
tumor, for those classified as having a high risk of recurrence and progression, the recommended treatment is 
the instillation of Mycobacterium bovis bacillus Calmette-Guérin (BCG)2. The immune system activation by the 
mycobacterium is key for this therapy to prevent recurrence and progression of the disease, however, the detailed 
mechanism of action is not completely understood3.
The bladder is the perfect cavity to allow close contact between a high concentration of bacilli and epithelial 
and resident immune cells. Thus, the presence of BCG in the bladder induces the local immune response which 
involves the release of cytokines and chemokines, initiating a critical immune cascade of events (detailed in excel-
lent reviews)4–6. Data from both mice models7 and BCG-treated patients8 showed that the infiltration of different 
kinds of immune cells is crucial for tumor clearance in the bladder9. Important constituents of the cellular inflam-
matory response to BCG include CD4+ and CD8+ lymphocytes, natural killer (NK) cells, and granulocytes3. In 
fact, infiltration of T cells is not observed when heat-killed BCG is instilled into mouse bladders7, suggesting that 
heat-killed BCG cannot replace live BCG to treat BC patients. The systemic immune reaction after the intraves-
ical instillation of BCG is less well understood, although previous studies have shown that cellular and humoral 
systemic responses could have a role in or be used as markers of the efficacy of BCG therapy7,10.
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We have recently proposed different strategies to improve both the safety and efficacy of BC treatment: the use 
non-pathogenic mycobacteria, such as Mycobacterium brumae and the use of an improved vehicle to instill the 
mycobacteria into the bladder. Regarding the former strategy, M. brumae showed antitumor activity against blad-
der cells in in vitro, ex vivo and in vivo assays in an orthotopic model of the disease, which would a safer alterna-
tive for BCG treatment11. Regarding the vehicle, formulating mycobacteria in an olive oil (OO)-in-water emulsion 
provided a homogeneous suspension of mycobacteria, avoiding the formation of aggregates that could interfere 
with the interaction between mycobacteria and immune cells12. OO-in-water mycobacteria also have proper 
physico-chemical properties that potentially facilitate close contact between mycobacteria and the epithelium12.
These new options for treatment, including the use of M. brumae and possibility of formulating both BCG and 
M. brumae, provide an excellent opportunity to understand how the mycobacteria-induced immune system helps 
to combat bladder tumors and how the responses differ between mycobacteria treatments and/or the role of the 
vehicle, if any. For the first time, we will examine the entire immune response triggered by these treatments in an 
orthotopic model of the disease.
Results
Treatment with mycobacteria triggers influx of immune cells into mouse bladders, which was 
higher when mycobacteria were emulsified. Immune cell infiltration into the bladder, one week after 
the last treatment, was analyzed by flow cytometry (gating strategy Supplementary Fig. 1). After gating lympho-
cytes by morphological parameters, only living lymphocytes (defined as AquaDead−CD45+ cells) were selected. 
B cell (CD19+), NK cell (CD3−NK1+), NKT cell (CD3+NK1+) and T cell (CD3+CD4+ and CD3+CD8+) subsets 
were analyzed.
The results show that all mycobacteria treatments induced the infiltration of lymphocytes into the bladder 
(Fig. 1). Significant differences in the absolute number of infiltrated T cells (both CD4+ and CD8+ T cells) between 
controls and mycobacteria-treated mice regardless of the vehicle used were observed (Fig. 1). When treatments 
were compared among them, a higher infiltration of immune cells in bladders from OO-E treated animals than 
in the Non-E treated animals was observed, and the number of total CD3 and CD4 subset in BCG-treated mice 
was significant (Fig. 1). The infiltration of NK and NKT cells was also demonstrated after mycobacteria treatment. 
Concerning these cells, significant differences between non-treated and mycobacteria-treated mice were found 
only when OO-E mycobacteria were intravesically instilled, for both BCG and M. brumae treatments (Fig. 1). 
Finally, no differences in infiltrated B cells were found between non-treated mice and BCG or M. brumae-treated 
mice, as shown in Fig. 1.
Figure 1. Infiltrated immune cells into mycobacteria-treated and non-treated tumor bearing mice 29 days after 
tumor induction. Absolute number of T cells (CD3+, CD4+ and CD8+ subsets), NKT cells, NK cells and B cells 
that infiltrated the bladder. The different groups of animals are indicated using different colors on the horizontal 
axis of the graph: non-mycobacteria treated mice (No-bact) are represented by empty black symbols, BCG-
treated mice by blue symbols and M. brumae-treated mice by red symbols. Dots represent animals treated with 
emulsion or emulsionated mycobacteria, triangles represent mice treated with PBS or mycobacteria in PBS. 
*p < 0.05; **p < 0.01.
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The IHQ findings confirmed the results obtained by cytometry analysis. First, we observed that the presence 
of tumors inside the bladders triggered the infiltration of some CD3+ cells and few CD20+ cells (B cells). The 
treatment of tumor-bearing mice with mycobacteria induced the infiltration of both CD3+ and CD20+ cells in 
the lamina propria and in some cases numerous CD3+ cells had infiltrated (Fig. 2). Regarding the localization of 
the populations, the IHQ analysis showed that CD3+ cells were generally localized in the peritumoral area in the 
animals that had tumors, regardless of whether the tumors were diffuse cells or solid masses.
KC, IL-6, MIP-2, MMP-9 and VEGF are present in urine samples from mycobacteria-treated 
tumor-bearing mice. Among all of the molecules studied in the urine samples, only IL-6, KC, VEGF, MIP-2 
and MMP-9 levels were detected in the groups of studied mice. Other molecules, such as IFN-γ, IP-10, GM-CSF, 
or TNF-α, were detected only in some groups at determined time-points while the remaining molecules (IL-1β, 
IL-2, IL-4, IL-5, IL-10, IL-12 p70, IL-13, IL-17, MCP-1 and RANTES) were under the limit of detection of the kit. 
Although using pooled samples did not allow us to calculate significant differences between treatment groups, 
a trend was observed, as shown in Supplementary Fig. 2. Regarding IL-6 and KC, an increase in their presence 
was observed in urine samples from all of the mice and was notably higher in mice treated with emulsified BCG. 
Regarding VEGF and MIP-2, while healthy mice had low levels at all time-points, a peak of production was 
detected at day 15 after tumor induction in all of the tumor-bearing mice regardless of whether they received 
mycobacteria treatment. In general, from day 15 to 29 after tumor induction, the levels of these molecules 
decreased except in the untreated tumor-bearing mice (No-bact groups). Concerning MMP-9, a general trend 
was observed in all of the groups, showing a production peak two days after tumor induction and decreasing 
levels of this molecule were then detected in the following weeks.
Mycobacteria treatment induces the production of BCG and M. brumae specific antibodies. 
When the production of anti-BCG and anti-M. brumae IgG antibodies was analyzed in serum samples from 
BCG-treated and M. brumae-treated mice, respectively, significant IgG production in all mycobacteria-treated 
groups compared to healthy mice and non-treated tumor-bearing mice was observed (Fig. 3a,b). In both BCG- 
and M. brumae-treated mice, higher levels of antibodies were present in sera from animals treated with emulsified 
mycobacteria than those treated with non-emulsified mycobacteria, although the differences were not signifi-
cant. High levels of anti-M. brumae antibodies were found in M. brumae-treated mice compared to the other 
groups (Fig. 3b). A cross-reaction antibody response between M. brumae and BCG was also studied. As shown in 
Fig. 3a,b, the presence of anti-BCG IgG levels in sera from M. brumae-treated mice were detected, and viceversa, 
although the levels were not higher than those detected against the antigen used for treatment. This result suggests 
the presence of shared antigens among them, as expected, as well as mycobacteria specific antigens. In all groups, 
the presence of anti-mycobacteria IgA antibodies in sera was insignificant (data not shown).
Splenocytes from mycobacteria-treated mice specifically proliferate in the presence of the 
antigens used in the instillations. To demonstrate a systemic immune response to emulsified and 
non-emulsified mycobacteria after intravesical instillation, splenocyte proliferation from sacrificed mice was 
measured after ex vivo restimulation. First, unspecific proliferation was observed in all cultures after stimulation 
with Concanavalin A. When splenocytes were stimulated in vitro with the same mycobacterium that was used for 
Figure 2. Representative histological images of bladder sections stained with two immunological markers. 
Bladders from the OO-E No-bact group (top) and from the OO-E live M. brumae group (bottom). Sections 
were stained with a CD3 marker (left column) and CD20 marker (right column). Scale bar, 100 µm.
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Figure 3. Systemic immune responses in tumor-bearing and healthy mice. Levels of anti-BCG (a) and anti-M. 
brumae (b) IgG antibodies present in sera from BCG-treated, M. brumae-treated and non-treated tumor-
bearing mice, as well as in healthy animals. The presence of BCG antibodies in M. brumae-treated mouse 
serum is represented by empty blue symbols (b) and the presence of M. brumae antibodies in BCG-treated 
mouse serum by empty red symbols (a). For a and b, solid lines represent the mean of the OD (405 nm) 
values (two technical replicates) of the six mice from each group. *p < 0.05 compared to No-bact. &p < 0.05 
compared to H. Splenocyte proliferation after ex vivo BCG (c) and M. brumae (d) restimulation. Proliferation 
is expressed relative to non-restimulated splenocytes of the same animal (proliferation of restimulated 
splenocytes/proliferation of non-restimulated splenocytes) after BCG and M. brumae stimulation. Proliferation 
of splenocytes from M. brumae-treated animals restimulated with BCG antigens is represented by empty red 
symbols (c) and proliferation of splenocytes from BCG-treated animals restimulated with M. brumae antigens 
is represented by empty blue symbols (d). For c and d, solid lines represent the mean of relative proliferation 
(three technical replicates) of 3–6 different spleens from each animal group. *p < 0.05 compared to No-bact. 
&p < 0.05 compared to H. For a, b, c, and d, dots represent animals treated with emulsified preparations and 
triangles represent animals treated with non-emulsified preparations. The different groups of animals are 
indicated by different colors on the horizontal axis of the graph as follows: empty grey triangles for the healthy 
(H) mice, empty black symbols for tumor-bearing mice receiving no mycobacteria treatment (No-bact), blue 
symbols for BCG-treated mice, and red symbols for M. brumae-treated mice.
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intravesical instillation, increased proliferation was observed in cultures from mycobacteria-treated mice com-
pared to those from non-treated tumor-bearing mice, which was significant in all cases except for non-emulsified 
M. brumae-treated mice (Fig. 3c,d). Again, an enhanced immune response was observed in splenocytes from 
emulsified-mycobacteria-treated mice compared to those obtained from non-emulsified mycobacteria-treated 
mice. When a possible cross-reaction was evaluated, the same trend mentioned for antibody detection was 
observed: higher proliferation was observed when the same mycobacteria were used for in vivo treatment and in 
vitro restimulation (Fig. 3c,d).
Discussion
This is the first study to investigate the local and systemic immune response of BCG compared to the promising 
and safe M. brumae immunotherapeutic agent. M. brumae is an efficacious tool for inhibiting bladder tumor 
growth both in vitro and in vivo, both formulated in an OO-in-water emulsion and non-emulsified11,12. M. bru-
mae is also an excellent immunostimulatory agent by triggering the production of cytokines in BC cells, mac-
rophages and peripheral blood in in vitro cultures11, but its immunotherapeutic role in vivo is unknown.
Our first relevant result is the induction of a massive infiltration of T lymphocytes into the bladder, both CD4+ 
and CD8+ T cells in M. brumae-treated tumor-bearing mice compared to the basal infiltration that is observed 
in non-treated tumor-bearing mice. This local immune response is similar to that induced by BCG. When for-
mulated mycobacteria were used, the immune cell infiltrate in the bladder was further increased, which was only 
statistically significant when CD3+ and CD4+ T cells were counted. The influx of immune cells into the bladder 
after treatment is critical in BC patients for a successful BCG treatment. Specifically, an increased intratumoral 
CD4+ T cell population has been significantly associated with BCG response and longer recurrence-free sur-
vival in BC patients8. The orthotopic murine model of the disease is a good model to evaluate this effect. Mice 
depleted of CD4 or CD8 populations showed decreased survival rates after tumor induction compared to immu-
nocompetent mice. Other than T cells, the remainder of the lymphocyte subset analysis also showed significant 
amounts of NK and NKT cell bladder infiltration when emulsified M. brumae or BCG was used for intravesical 
treatment. Brandau et al.13 also demonstrated that the BCG-induced presence of NK cells is relevant for control of 
the primary tumor by depleting this cell population in the orthotopic murine model. The fact that only emulsified 
mycobacteria significantly triggered the infiltration of these NK cells highlights the importance of the vehicle in 
which the therapeutic agents are instilled into the bladder. These results confirm that the oil-in-water emulsion 
allows the mycobacteria to reach the epithelium and exert their antitumor effect as we suggested previously12.
This profile of cellular infiltration triggered by M. brumae could be indicative of a biased favorable Th1 
response, as has been described for BCG. BCG responders release higher amounts of Th1 cytokines, such as 
IFN-γ, IL-12 or IL-2 than Th2 cytokines, such as IL-4, IL-5 or IL-10, in the urine. In contrast, if the response is 
similar to Th2, the therapy fails14,15. We measured the presence of a broad panel of cytokines and chemokines in 
mouse urine but our results were not conclusive mainly due to the amount of samples we obtained. Only five mac-
romolecules (IL-6, KC, VEGF, MIP-2 and MMP-9) were detected. Repeated instillations of mycobacteria might 
be responsible for the peak of IL-6 and KC observed at day 157,15–17 and was correlated with the influx of some 
immune cells detected by flow cytometry and immunohistochemistry (Figs 1 and 2). Furthermore, although IL-6 
induces the Th2 response, which might be controlled by the presence of IFN-γ and the absence of IL-418, IL-6 
also up-regulates the fibronectin α5β1 receptor, which is involved in the interaction of BCG with the urothe-
lium19,20, which inhibits bladder tumor cell proliferation. It is worth mentioning, our previous results showed 
that OO-in-water emulsified M. brumae has a higher affinity for fibronectin than non-emulsified mycobacteria12.
The second relevant result was the induction of a systemic, both humoral and cellular, immune response by 
M. brumae instillation, which was also enhanced when emulsified mycobacteria was used for treatment (Fig. 3). 
To the best of our knowledge, this is the first work that demonstrates a specific antibody production against 
M. brumae or BCG in the orthotopic murine model of the disease. Previous studies have demonstrated the pres-
ence of circulating anti-BCG antibodies in BC patients, with uncertainty on whether their presence correlates 
with a positive outcome21,22 of the treatment or whether it has any predictive value23,24. Apart from its use as a 
predictive biomarker for mycobacteria treatment in BC patients, whether the induction of this humoral response 
has a role in mycobacteria-induced immunotherapy requires further investigation. The orthotopic model can 
then be a useful tool. The other relevant result related to the systemic response was that the non-pathogenic 
mycobacterium M. brumae or M. brumae-derived antigens, could reach the spleen of treated mice as specific 
proliferation after restimulation (Fig. 3), and IFN-γ production12 was observed in cultured splenocytes from 
M. brumae-treated mice, identifying then memory immune cells in the spleen15. The synthesis of IFN-γ and 
the fact that IL-4 was not detected12, suggest that, although M. brumae elicits both humoral (Th2) and cellular 
(Th1) immune responses, this response was mainly biased to a Th1 response, as was the response to BCG14,25. 
Unlike BCG, which was isolated from splenocytes of BCG-treated tumor-bearing mice even four weeks after 
the last instillation, M. brumae was not found in the spleen cells one week after the last instillation, as we have 
previously shown in this orthotopic mouse model11,26. One possibility may be that M. brumae reached the blood-
stream in treated tumor-bearing mice and arrived at the spleen, like BCG, and was rapidly cleared. The ability 
of M. brumae to reach different organs after infection in healthy mice is currently being studied to elucidate the 
mechanism of its immunomodulatory capability. Moreover, our results shed light on another interesting fact. 
An expected cross-reaction is observed when sera or splenocytes from BCG-treated mice are in contact with 
M. brumae antigens and viceversa (Fig. 3), due to the presence of common mycobacteria antigens. However, 
although not significant, a trend was observed towards specificity in this cross-reactive response. Interestingly, 
cross-reactive stimulation of splenocytes resulted in no IFN-γ production in supernatant cultures by these cells 
(data not shown), indicating that it is necessary to restimulate with the same antigens with which the animals 
were treated to trigger IFN-γ production, as observed with the splenocyte proliferation. Thus, both humoral 
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and restimulatory reactions suggest that some M. brumae- or BCG-specific antigens could be implicated in the 
systemic immune response.
Despite known limitations, such as using exclusively female mice or the variability of tumor cells implanted 
into the bladder27, which could also lead to variability in the immune response generated by mycobacteria treat-
ment, the orthotopic murine BC model is a solid, well-recognized model that provides consistent results to eval-
uate the immune response triggered by potential new antitumor therapies, such as IL-12 plus chitosan28, or the 
synergy of different treatments29. However, one drawback of our study is the low number of mice that survived 
until day 29 after tumor induction in the non-treated group of animals due to the high mortality rates in this 
group. It has previously been demonstrated that at least three to four BCG weekly instillations are needed in 
healthy mice to observe the infiltration of immune cell populations into the bladder, reaching a peak 28–30 
days after initiating the treatment7. More animals in the non-treated tumor-bearing mouse group could provide 
significant differences between mycobacteria-treated and non-treated mice in regard to some of the immune 
parameters analyzed. In view of our results, further investigation is warranted to elucidate the complete immune 
response (other immune subsets of cells or local and systemic immune biomarkers) induced by M. brumae com-
pared to BCG to completely understand the role of mycobacteria in modulating the tumor microenvironment. 
Different strategies for superficial bladder treatment are currently being proposed: diverse bacteria30–32, modi-
fied virus33,34, chemotherapeutic agents35, molecules that target specific immune receptors36, peptide vaccines37, 
plant derived compounds38, etc. Mycobacteria can have a role to synergy to these treatments, as has been already 
demonstrated35,37,38, enabling to reduce the toxicity and resistance to a single treatment. Further understanding of 
the immune reaction associated with mycobacteria treatment could be critical for identifying the benefits of new 
immunotherapeutic possibilities.
In summary, we showed that M. brumae triggers selective infiltration of immune cells into the bladder similar 
to BCG, inducing a favorable systemic immune response in treated tumor-bearing mice.
Material and Methods
Bacterial strains and cell line. M. bovis BCG Connaught (ATCC 35745) and M. brumae (ATCC 51384TM) 
were grown on Middlebrook 7H10 medium (Difco Laboratories, Surrey, UK) supplemented with 10% oleic-al-
bumin-dextrose-catalase enrichment, for 4 or 1 week, respectively, at 37 °C. For in vitro stimulation of spleno-
cytes and for coating enzyme-linked immunosorbent assay (ELISA) plates, suspensions of M. brumae or BCG 
were heat-killed at 121 °C for 30 minutes39. Mycobacteria emulsified in OO (Sigma) were prepared as previously 
described12. For tumor induction, MB49 BC murine cells were cultured as previously described11,26.
Orthotopic murine model of BC and intravesical treatment. Animal experiments were performed 
according to procedures approved by the Animal Care Committee at the Universitat Autònoma de Barcelona. 
The orthotopic murine model of BC was developed as previously described11,26. Briefly, six C57Bl/6 female mice 
(6–8 weeks old; Charles River Laboratories, France) were anaesthetized and chemical lesions were induced by 
intravesical instillation of L-poly-lysine (Sigma). Subsequently, 105 MB49 bladder tumor cells were instilled to 
induce tumors. One day later, each group of mice received intravesically 100 µl of mycobacteria suspensions (cor-
responding to 2 × 106 colony forming units (CFU) of BCG or 2 × 107 CFU of M. brumae per mouse) or vehicle for 
control groups. Animals were treated weekly following the schedule shown in Fig. 4 and were sacrificed at day 29 
after tumor induction. At the time of sacrifice, blood was collected and bladders and spleens aseptically removed. 
Bladders from some of the animals of each group were processed for immunohistochemistry (IHQ) analysis, and 
the other bladders for cytometry studies.
Detection of infiltrated immune cell subsets in bladders. For flow cytometry experiments, bladders 
were minced using a scalpel followed by digestion with Roswell Park Memorial Institute (RPMI) medium sup-
plemented with 5% fetal bovine serum (FBS) containing 0.5 mg/mL collagenase II (Sigma, Spain) at 37 °C for 
two successive 30 min cycles, with continuous shaking. The cell suspension obtained was consecutively filtered 
through a 70-μm disposable plastic strainer (Becton & Dickinson) and pelleted for staining. The cells were labeled 
with the following antibodies: PerCP-CD45 and PECy7-NK1.1, purchased from Biolegend, FITC-CD3, PE-CD4, 
APC-CD8, PE-CD19 and APC-CD11b, from Immunotools. The lymphocyte gate was defined by morphological 
parameters, and dead cells were excluded using a live/dead fixable Aqua Dead Cell Stain kit (Invitrogen). Samples 
were acquired in a LSRII flow cytometer (Becton & Dickinson), and the data were analyzed using FlowJo software 
Figure 4. Schedule of the animal experiments. Graphical representation of the schedule, in which tumor 
induction (day 0), mycobacteria treatments (days 1, 8, 15 and 22 after tumor induction) and sacrifice (day 29 
after tumor induction) are indicated by arrows.
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(9.8 v; TreeStar, Portland, OR, USA). Absolute cell numbers were obtained by using Perfect-Count Microspheres 
(Cytognos).
For IHQ, 3-µm paraffin-embedded tissue sections were dewaxed and endogenous peroxidase activity blocked 
by exposure to 3% H2O2 for 40 min. For antigen retrieval, sections were treated with 0.1% protease (Sigma) in PBS 
for 8 min at 37 °C (CD3) or boiled in bain-marie at 96–98 °C for 20 min in 0.01 M citrate buffer (pH 6.0) (CD20). 
Non-specific protein binding was blocked with normal goat serum (X0907, Dako) or normal rabbit serum 
(X0902, Dako) for 1 h at room temperature (RT). T-cell and B-cell immunolabeling was performed using a pol-
yclonal rabbit anti-human CD3 antibody (Dako) diluted 1:300 or CD20/ MS4A1 antibody (Thermo Scientific™ 
Pierce™) diluted 1:200, respectively, overnight (ON) at 4 °C. The positive control tissue consisted of sections of 
normal mouse lymph node. An EnVisionTM+ System-HRP Rabbit Kit (Dako) was used to detect CD3 and CD20. 
The chromogen substrate was 3,3′-diaminobenzidine (Dako). The sections were counterstained with hematoxylin 
(Merck). Negative control sections from the same specimens were identically processed, replacing the specific 
primary antibody with an isotype-control IgG of the same species and concentration as the primary antibody.
Detection of macromolecules in urine samples. To detect macromolecules, pools of urines from each 
group of animals were collected at different time-points: day 0, before tumor induction; day 1, before the first 
dose of treatment; days 2 and 15, 24 h after the intravesical treatment; and day 29, before sacrificing the ani-
mals. Collected urine samples were centrifuged, stabilized in stabilization buffer15 and frozen at −40 °C. Thawed 
urine samples were diluted 1:2 in Calibrator Diluent RD6-52 (R&D Biosystems) and analyzed for the presence 
of mouse granulocyte–macrophage colony-stimulating factor (GM-CSF), interferon (IFN)-γ, IFN-γ-inducible 
protein-10 (IP-10), interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 p70, IL-13, IL-17, keratinocyte 
chemoattractant (KC), macrophage inflammatory protein-2 (MIP-2), matrix metaloproteinase-9 (MMP-9), 
monocyte chemoattractant protein-1 (MCP-1), regulated on activation, normal T cell expressed and secreted 
(RANTES), tumor necrosis factor-α (TNF-α), and vascular endothelial growth factor (VEGF) using a multiplex 
kit (R&D Biosystems). The assay was performed following the manufacturer’s instructions. The plate was read 
using Luminex® Magpix® equipment. xPONENT® 4.2 software was used for quantitative data acquisition and 
Milliplex® Analyst 5.1 for multiplex data analysis.
Detection of anti-mycobacteria antibodies in sera. Mice were bled by cardiac puncture when sac-
rificed; sera were collected after blood centrifugation and kept at −40 °C until use. ELISA plates (Costar) were 
coated with either heat-killed BCG or M. brumae cells (20 µg/mL) in carbonate–bicarbonate buffer (pH 9.6) ON 
at RT40,41. After washing with Tris-buffered saline (TBS), the wells were blocked with 0.5% gelatin (Sigma) in TBS 
(blocking buffer) for 2 h42. After 3 washes, serum samples were diluted 1/50 in blocking buffer for IgG and without 
dilution for IgA detection and were incubated ON at RT. The plates were then washed and incubated for 1 h at RT 
with alkaline phosphatase-labeled goat anti-mouse IgG or IgA antibodies (Southern Biotech, Birmingham, AL, 
USA) diluted in blocking buffer. The enzyme–substrate reaction was developed using p-nitrophenyl phosphate 
(Sigma), and the absorbance was measured in a multiscan reader at 405 nm (Tecan). Blank wells (without antigen) 
were included for each sample, and the absorbance values were deducted from those obtained in antigen-coated 
wells.
Proliferation of mycobacteria-stimulated splenocyte cultures. Spleens were individually disrupted 
in SensiCellTM RPMI medium 1640 with glucose, sodium pyruvate and stable glutamine (Life Technologies) 
supplemented with 10% FBS (complete medium). Splenocyte suspensions were allowed to settle at 4 °C for at 
least 30 min. Supernatants were collected and the cell concentration was adjusted to 3 × 106 cells/mL in complete 
RPMI medium with penicillin (100 U/mL) (ERN, Spain) and streptomycin (100 µg/mL) (Reig Jofre, Spain). One 
hundred microliters was added to 96-well flat-bottomed microtiter plate (Nunc, Denmark) wells with or with-
out 1 mg/mL of heat-killed BCG or M. brumae cells or 5 µg/mL of Concanavalin A (ConA, Sigma) as a positive 
control. After incubation for 72 hours at 37 °C in 5% CO2, supernatants were collected, and cell proliferation 
was measured using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described 
previously43,44.
Statistical analysis. A t-test was used to compare flow cytometry data and the proliferation of splenocytes 
(GraphPad Prism). Immunoglobulin levels in sera samples were compared using a Mann-Whitney U test using 
GraphPad Prism software. Significance was defined as p < 0.05.
Data Availability
All data generated or analysed during this study are included in this published article (and its Supplementary 
Information files).
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